Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Ju Dong Yang MD, MS

Ju Dong Yang MD, MS

Medical Director, Liver Cancer Program, Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California

The research program of Ju Dong Yang, MD, has been focused on clinical and translational research of liver cancer. Dr. Yang conducted population-based cohort studies to describe recent trends in liver cancer epidemiology in the United States. He published outcome research papers in liver cancer. Dr. Yang has also conducted modeling studies and proposed a survival prediction model in liver cancer patients. He has also conducted a multistate Markov model study and investigated the impact of liver cancer surveillance on overall survival in patients with cirrhosis. In addition, Dr. Yang has been interested in liver cancer health disparities research from a global perspective. His research highlighted that Africans have a very early onset of HCC with extremely poor survival. Finally, Dr. Yang has been interested in liver cancer biomarker research. He and his colleagues have reported that circulating tumor cells (CTC) are detectable in liver cancer patients and are independent predictors of patient survival. Our more recent study indicated that circulating cell-free tumor DNA mutation and methylation and extracellular vesicles are promising diagnostic or prognostic biomarkers in liver cancer. Dr Yang`s research is currently being funded by NIH/NCI, DoD and the American College of Gastroenterology.

Disclosures

Dr. Yang reports the following: Consultant or Advisory Role: AstraZeneca, Eisai, Exact Sciences, Exelixis, Fujifilm Medical Sciences, Merck and Gilead Sciences ai, Eximus, Fujifilm, and Gilead Sciences, all outside of the submitted work.